Molecule Details
InChIKeyMZPVEMOYADUARK-UHFFFAOYSA-N
Canonical SMILESC=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)2
Pfam Stratification Homologous
Avg pChEMBL7.89
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB16272
Drug NameOrelabrutinib
CAS Number1655504-04-3
Groups investigational
ATC Codes L01EL04
DescriptionOrelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
Categories: Antineoplastic Agents Antineoplastic and Immunomodulating Agents Bruton's tyrosine kinase (BTK) inhibitors Protein Kinase Inhibitors
Cross-references: BindingDB: 389631 CHEMBL4650321 ChemSpider: 82956396
Target Activities (2)
Target Gene Organism Category Pfam pChEMBL Type Source
Q06187 BTK Homo sapiens Human PF00779 PF00169 PF07714 PF00017 PF00018 8.4 IC50 ChEMBL;BindingDB
P42680 TEC Homo sapiens Human PF00779 PF00169 PF07714 PF00017 PF00018 7.4 IC50 ChEMBL
DrugBank Target Actions (1)
Target Gene Target Name Action Type
Q06187 BTK Tyrosine-protein kinase BTK inhibitor targets